Compare Boston Scientific Corporation (BSX) vs Enbridge Inc (ENB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Enbridge Inc — how do they compare? Boston Scientific Corporation trades at $43.55 (market cap $66.37B), while Enbridge Inc trades at $56.26 (market cap $121.05B). The key difference: Enbridge Inc is the larger of the two by market cap, and Enbridge Inc pays a 5.03% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | ENB | |
|---|---|---|
Market Cap | $66.37B | $121.05B |
Sector | Health | Energy |
52-Week High | $108.14 | $58.04 |
52-Week Low | $42.63 | $44.59 |
Enterprise Value | $75.94B | $201.85B |
Dividend Yield | — | 5.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Enbridge (ENB) trades at $55.07, up 0.75% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $65.19 billion in 2025, with net income of $7.49 billion, though it missed Q3 2025 EPS estimates. Analyst sentiment is balanced with a 48% buy rating, and the stock offers a dividend yield supported by over $28 billion in growth projects. Recent news highlights its role in energy infrastructure and AI-driven power demand.
Outlook is cautiously optimistic due to solid cash flow and dividend sustainability, but risks include high debt levels and sensitivity to energy markets. The stock presents a value opportunity for income-focused investors, with earnings on July 31, 2026, as a key near-term catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
